Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Problems with UK government's risk sharing scheme for assessing drugs for multiple sclerosis.

× No keyword cloud information.

33 in total

1. Evidence of interferon beta-1a dose response in relapsing-remitting MS: the OWIMS Study. The Once Weekly Interferon for MS Study Group.

Authors:
Journal: Neurology Date: 1999-09-11 Impact factor: 9.910

Review 2. Disease-modifying drugs for multiple sclerosis: a rapid and systematic review.

Authors: A Clegg; J Bryant; R Milne
Journal: Health Technol Assess Date: 2000 Impact factor: 4.014

Review 3. Interferon in relapsing-remitting multiple sclerosis.

Authors: G P Rice; B Incorvaia; L Munari; G Ebers; C Polman; R D'Amico; G Filippini
Journal: Cochrane Database Syst Rev Date: 2001

4. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group.

Authors: L D Jacobs; R W Beck; J H Simon; R P Kinkel; C M Brownscheidle; T J Murray; N A Simonian; P J Slasor; A W Sandrock
Journal: N Engl J Med Date: 2000-09-28 Impact factor: 91.245

5. The natural history of multiple sclerosis: a geographically based study. 7. Progressive-relapsing and relapsing-progressive multiple sclerosis: a re-evaluation.

Authors: M Kremenchutzky; D Cottrell; G Rice; W Hader; J Baskerville; W Koopman; G C Ebers
Journal: Brain Date: 1999-10 Impact factor: 13.501

6. Randomized controlled trial of interferon- beta-1a in secondary progressive MS: Clinical results.

Authors:
Journal: Neurology Date: 2001-06-12 Impact factor: 9.910

7. Long-term treatment of multiple sclerosis with azathioprine.

Authors: W R Swinburn; L A Liversedge
Journal: J Neurol Neurosurg Psychiatry Date: 1973-02 Impact factor: 10.154

8. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study.

Authors: G Comi; M Filippi; F Barkhof; L Durelli; G Edan; O Fernández; H Hartung; P Seeldrayers; P S Sørensen; M Rovaris; V Martinelli; O R Hommes
Journal: Lancet Date: 2001-05-19 Impact factor: 79.321

9. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging--measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group.

Authors: G Comi; M Filippi; J S Wolinsky
Journal: Ann Neurol Date: 2001-03 Impact factor: 10.422

10. Randomized versus historical controls for clinical trials.

Authors: H Sacks; T C Chalmers; H Smith
Journal: Am J Med Date: 1982-02 Impact factor: 4.965

24 in total

1. Shared scheme for assessing drugs for multiple sclerosis: why are eyes tightly shut to considering causes other than autoimmunity?

Authors: Abhijit Chaudhuri; Peter O Behan
Journal: BMJ Date: 2003-05-31

2. Shared scheme for assessing drugs for multiple sclerosis: dealing with uncertainties about cost effectiveness of treatments is difficult problem.

Authors: David Chadwick; Richard Gray
Journal: BMJ Date: 2003-05-31

3. Shared scheme for assessing drugs for multiple sclerosis: cost effective provision of effective treatments for multiple sclerosis.

Authors: Jacqueline C Napier; Richard Francis; Glyn Wright
Journal: BMJ Date: 2003-05-31

4. Neuropsychotherapeutics in the UK: what has been the impact of NICE on prescribing?

Authors: Tom Walley
Journal: CNS Drugs Date: 2004 Impact factor: 5.749

5. Access to high cost drugs in Australia.

Authors: Christine Y Lu; Ken Williams; Ric Day; Lyn March; Lloyd Sansom; James Bertouch
Journal: BMJ Date: 2004-08-21

Review 6. Using comparative effectiveness research to inform policy and practice in the UK HHS: past, present and future.

Authors: Kalipso Chalkidou; Tom Walley
Journal: Pharmacoeconomics Date: 2010 Impact factor: 4.981

7. Public funding of bosentan for the treatment of pulmonary artery hypertension in Australia: cost effectiveness and risk sharing.

Authors: John H Wlodarczyk; Leslie G Cleland; Anne M Keogh; Keith D McNeil; Kate Perl; Robert G Weintraub; Trevor J Williams
Journal: Pharmacoeconomics Date: 2006 Impact factor: 4.981

Problems with UK government's risk sharing scheme for assessing drugs for multiple sclerosis.